Drug Profile
Research programme: Tat-TAR interaction inhibitors - PTC Therapeutics
Latest Information Update: 28 Aug 2007
Price :
$50
*
At a glance
- Originator PTC Therapeutics
- Class
- Mechanism of Action Human immunodeficiency virus tat gene product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 27 Jul 2001 PTC Therapeutics has received a phase I SBIR grant for this programme from the NIH
- 17 Jan 2001 New profile
- 17 Jan 2001 Preclinical development for HIV infections treatment in USA (Unknown route)